Quality initiatives in drug discovery fail on a regular basis. One of the key reasons for failure is frequently overlooked - Emotions.
Frequently, quality initiatives in drug discovery fail miserably. The expected outcome and the expected positive impact on Innovation Productivity never materialises. Simply because a basic fact is ignored throughout the entire process: running quality initiatives in drug discovery is an emotionally loaded activity.
Firstly, running quality initiatives in drug discovery implies a certain necessity to do so, which is equal to the allegation of the existing quality level being deficient. Since most scientists firmly believe in the quality of their work, criticism in this field is usually not welcome.
Secondly, the resulting quality processes have in-built elements of control. Seen from the perspective of a “quality-unmolested” discovery unit, introducing quality systems is a transformation from joyful and free scientific work to a “big brother is watching” scenario. The prospect is usually not well received.
Thirdly, in the course of the average quality initiative, two special groups are expected to work together, drug discovery scientists and QA professionals.
Since members of both groups often cherish their ignorance of the other groups requirements and frequently express this attitude quite freely, interaction of both tends to be stressed. In our experience, drug discovery scientists and QA discussing quality is a cultural clash waiting to happen.